Melanoma Drug Therapy Survey

This survey is now closed

If you have any questions please contact us at 1.877.560.8035 or email mzawadzki@melanomanetwork.ca

Survey closes January. 4th. 2021. 

About The pan-Canadian Oncology Drug Review, (pCODR)

The pan-Canadian Oncology Drug Review, (pCODR) is an evidence-based, cancer drug review process in Canada. The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada’s provinces and territories (except Quebec) in guiding their drug funding decisions. Under the pCODR process, detailed assessments are conducted by a pan-Canadian expert review committee, with opportunities for input by patient advocacy groups (like MNC), the pharmaceutical industry, clinician-based tumour groups, and the provincial advisory group.

Click Here to visit CADTH for more detials on encorafenib and binimetinib.

Find Support 

Melanoma Network of Canada offers free support services for melanoma and skin cancer patients.

Melanoma Support Groups

Connect with patients facing similar experiences. Join our virtual Melanoma Support Group.

Skin Cancer Patient Forum

A place to ask questions or provide insights and information on your own experience with other patients and caregivers.

Menu